文献速递其他结缔组织病

吗替麦考酚酯降低局限性皮肤型系统性硬化血管并发症相关治疗升级风险

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-04-17

基于意大利SPRING注册队列的靶试验模拟,评估吗替麦考酚酯(MMF)在局限性皮肤型系统性硬化(lcSSc)中对血管并发症相关治疗升级的影响。107对倾向评分匹配后,MMF组血管活性/血管扩张治疗升级发生率为0.3/100患者年,对照组为5.4/100患者年,风险比0.05(95%CI 0.01-0.38,P=0.004)。

要点

  • MMF在lcSSc中处方率较低,多见于男性、抗Scl70阳性、合并间质性肺病或肌炎者。
  • 匹配后MMF组血管并发症相关治疗升级风险显著低于对照组(HR 0.05)。
  • 结果提示MMF可能有助于预防lcSSc血管并发症,需进一步前瞻性验证。

核心结论

  • 在lcSSc患者中,引入MMF减少了因血管并发症而升级血管活性或血管扩张治疗的需求,提示其可能有助于预防血管并发症。

研究设计与样本

  • 回顾性队列研究,纳入意大利系统性硬化进展调查(SPRING)注册的1435例lcSSc患者,其中152例接受MMF。
  • 采用基于人口学、临床特征和基线治疗的滚动入组时间依赖倾向评分,将107例MMF治疗患者与未治疗对照匹配。
  • 主要结局为60个月内因未控制或新诊断血管并发症而加用伊洛前列素、内皮素受体拮抗剂或磷酸二酯酶-5抑制剂。

主要发现

  • MMF处方更常见于男性、抗Scl70阳性、抗着丝点抗体阴性、合并间质性肺病或肌炎、无指端溃疡史的患者。
  • 中位随访40.5个月(四分位距23.3-60.0),MMF组血管活性/血管扩张治疗升级发生率为0.3/100患者年,匹配对照组为5.4/100患者年。
  • 两组无治疗升级生存率差异显著,风险比0.05(95%CI 0.01-0.38,P=0.004)。

关键数值与推荐

  • 治疗升级定义为在现有治疗基础上因未控制或新诊断血管并发症而加用伊洛前列素、内皮素受体拮抗剂或磷酸二酯酶-5抑制剂。
  • 匹配后MMF组与对照组治疗升级风险比0.05(95%CI 0.01-0.38,P=0.004)。

临床怎么用

  • 对于lcSSc患者,尤其是男性、抗Scl70阳性、合并间质性肺病或肌炎者,可考虑MMF治疗以降低血管并发症相关治疗升级风险。
  • MMF可能具有超越纤维化控制的血管保护作用,但需结合个体情况谨慎评估。

局限性

  • 回顾性注册研究设计,可能存在未测量混杂。
  • 匹配后样本量有限(MMF组107例),事件数较少。
  • 结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function. Our aim was to evaluate the reasons for prescribing MMF treatment in patients with lcSSc and its impact on the need for escalation of vascular complication-related treatments during follow-up. METHODS: Patients with lcSSc enrolled in the Italian Systemic Sclerosis Progression Investigation registry were retrospectively evaluated. All patients treated with MMF were matched to patients not treated with MMF, which was based on a roll-entry time-dependent propensity score built on demographics, clinical features, and baseline treatment. The escalation of vasoactive or vasodilator treatment up to 60 months was defined as the introduction of iloprost, endothelin receptor antagonists, or phosphodiesterase-5 inhibitors on top of the ongoing treatment, because of uncontrolled or newly diagnosed vascular complications. A hazards Cox model was also adopted to quantify the association of MMF treatment with treatment escalation. RESULTS: A total of 1,435 patients with lcSSc were evaluated, of whom 152 were prescribed MMF (17.1% male; mean age at lcSSc onset 48.7 ± 13.9 years, 54.6% anti-Scl70 positive). The prescription of MMF was more common in men and in anti-Scl70 positive, anticentromere negative patients with interstitial lung disease, myositis, and without a history of digital ulcers. After matching 107 patients with MMF-untreated controls, the overall incidence of vasoactive/vasodilator treatment escalation events related to digital ulcers over a median follow-up of 40.5 months (interquartile range 23.3-60.0) was 0.3 per 100 patient-years in the MMF-treated group and 5.4 per 100 patient-years in the matched control group, with a significant difference in treatment escalation-free survival between the two groups (hazard ratio 0.05, 95% confidence interval 0.01-0.38; P value = 0.004). CONCLUSION: In patients with lcSSc, the introduction of MMF has reduced the need for escalation of vasoactive or vasodilator treatment, suggesting that it may also help to prevent vascular complications, which frequently affect patients with lcSSc.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. De Lorenzis E, Natalello G, De Angelis R, et al. Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry. Arthritis Care Res (Hoboken). 2026. PMID: 41466450. doi:10.1002/acr.70039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。